Documented infections due to organisms producing inducible β-lactamases or Extended-Spectrum β-lactamases (ESBL) resistant to alternate agents.
Empiric Treatment of life-threatening infections where multi-drug resistant organisms suspected (i.e. severe sepsis, neutropenic patient with absolute neutrophil count < 0.5).
Therapy of P. aeruginosa infections where other agents cannot be used due to allergy or toxicity.
Therapy of documented or suspected infections due to MRSA, Enterococcus spp., Stenotrophomonas maltophilia, Chlamydia spp. and Mycoplasma spp.
Treatment of infections due to organisms susceptible to less costly and/or narrower-spectrum agents
Treatment of meningitis or other Central Nervous System Infection (Meropenem is only carbapenem with an indication for CNS infection)
Immediate and delayed-type allergy
Cytopenias, positive Coombs
Liver enzyme abnormalities
CNS effects including confusional states and seizures
May decrease serum concentrations of valproic acid
Ganciclovir/valganciclovir - may increase risk of seizures
Cyclosporine - may enhance neurotoxic effects of imipenem
- 500 mg or less: dilute in 100 mL D5W or NS and administer over 30 min.
- 750 mg or 1000 mg: dilute in 250 mL D5W or NS , infuse over 60 min
EH Prescribing Restrictions
None (Pharmacist reviews therapy)
Community IV Formulary (Metro Area)
NO - Limited stability
Antimicrobial class: Carbapenem
Pregnancy category: C
CSF penetration: Not indicated for CNS infection - use meropenem